A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 12 Jun 2018 Results (n=48) published in the British Journal of Clinical Pharmacology.
- 08 Sep 2015 Status changed from not yet recruiting to completed as per ClinicalTrials.gov record.
- 23 Mar 2015 New trial record